A carregar...
Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
Rifaximin, with its low systemic absorption, may represent a treatment of choice for irritable bowel syndrome (IBS), mainly due to its ability to act on IBS pathogenesis, through the influence on gut microbiota. The aim of the present study was to assess, by biomolecular tools, the rifaximin active...
Na minha lista:
| Publicado no: | Clin Exp Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4675645/ https://ncbi.nlm.nih.gov/pubmed/26673000 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEG.S89999 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|